Order Article Reprints

Occhipinti M, Brambilla M, Galli G, Manglaviti S, Giammaruco M, Prelaj A, Ferrara R, De Toma A, Proto C, Beninato T, et al. Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. Journal of Personalized Medicine. 2021; 11(5):424. https://doi.org/10.3390/jpm11050424

Occhipinti, Mario, Marta Brambilla, Giulia Galli, Sara Manglaviti, Maristella Giammaruco, Arsela Prelaj, Roberto Ferrara, Alessandro De Toma, Claudia Proto, Teresa Beninato, and et al. 2021. "Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors" Journal of Personalized Medicine 11, no. 5: 424. https://doi.org/10.3390/jpm11050424

Occhipinti, M., Brambilla, M., Galli, G., Manglaviti, S., Giammaruco, M., Prelaj, A., Ferrara, R., De Toma, A., Proto, C., Beninato, T., Zattarin, E., Lo Russo, G., Gelibter, A. J., Simmaco, M., Preissner, R., Garassino, M. C., De Braud, F., & Marchetti, P. (2021). Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. Journal of Personalized Medicine, 11(5), 424. https://doi.org/10.3390/jpm11050424